Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis

References

• Amieva M R, El-Omar E M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008;134:306–23.
   PubMed Web of Science ®Google Scholar
• Correa P, Houghton J M. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659–72.
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–86.
   PubMed Web of Science ®Google Scholar
• Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2012;17:49–55.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275–8.
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808–25.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut 2012;61:646–64.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori Antibiotic Resistance: a Systematic. J Gastrointestin Liver Dis 2010;19:409–14.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–81.
   PubMed Web of Science ®Google Scholar
• Gisbert J P, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;26:495–500.
   PubMed Web of Science ®Google Scholar
• Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63:769–2802.
   PubMed Web of Science ®Google Scholar
• Anderson VR, Perry CM. Levofloxacin: a review of its use as a highdose, short-course treatment for bacterial infection. Drugs 2008;68:535–65.
   PubMed Web of Science ®Google Scholar
• Nista E C, Candelli M, Zocco M A, Cremonini F, Ojetti V, Finizio R, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006;101:1985–90.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339–43.
   PubMed Web of Science ®Google Scholar
• Bañares R, Albillos A, Rincón D, Alonso S, González M, Ruiz-del-Arbol L, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology 2002;35:609–15.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;31:1077–84.
   PubMed Web of Science ®Google Scholar
• Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: A double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785–90.
   PubMed Web of Science ®Google Scholar
• Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010;59:572–8.
   PubMed Web of Science ®Google Scholar
• Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med 2010;21:310–14.
   PubMed Web of Science ®Google Scholar
• Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother 2012;67:2254–9.
   PubMed Web of Science ®Google Scholar
• Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, Rivera M, et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005;37:571–6.
   PubMedGoogle Scholar
• Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, et al. Clarithromycin–amoxycillin-containing triple therapy: a valid empirical first-line treatment for helicobacter pylori eradication in Hong Kong? Helicobacter 2009;14:505–11.
   PubMed Web of Science ®Google Scholar
• Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC. Comparison of the once daily levofloxacin containing triple therapy with the twice daily standard triple therapy for first line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract 2010;64:1530–4.
   PubMed Web of Science ®Google Scholar
• Cavallaro L, Egan BJ, O’Morain C, Di Mario F. Treatment of Helicobacter pylori infection. Helicobacter 2006;11:36–9.
   PubMed Web of Science ®Google Scholar
• Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565–70.
   PubMed Web of Science ®Google Scholar
• O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection in 2011. Helicobacter 2011;16:53–58.
   PubMed Web of Science ®Google Scholar
• Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, et al. Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012;35:56–65.
   PubMed Web of Science ®Google Scholar
• Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971–5.
   PubMed Web of Science ®Google Scholar
• Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, et al. The optimal first-line therapy of helicobacter pylori infection in year 2012. Gastroenterol Res Pract 2012;2012:168361.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35–44.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic. J Gastrointestin Liver Dis 2010;19:409–14.
   PubMed Web of Science ®Google Scholar
• Díaz-Reganon J, Alarcon T, Domingo D, López-Brea M. Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors. Rev Esp Quimioter 2006;19:34–8.
   PubMedGoogle Scholar
• Cibrelus LA, Pérez de Ayala A, Alarcón T, Urruzuno P, Martínez MJ, López-Brea M. In vitro efficiency of Ciprofloxacin and rifampicin as potential second-line treatment in Spanish Helicobacter pylori clinical isolates. Helicobacter 2006;11:402–3.
   Web of Science ®Google Scholar
• Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61:1112–15.
   PubMed Web of Science ®Google Scholar
• Graham D Y, Dore M P. Helicobacter pylori therapy demystified. Helicobacter 2011;16:343–5.
   PubMed Web of Science ®Google Scholar
• Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, et al. Cervia II Working Group Report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782.
   PubMedGoogle Scholar
• Fischbach L, Evans E L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343–57.
   PubMed Web of Science ®Google Scholar
• Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374–84.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori Antibiotic Resistance: a Systematic. J Gastrointestin Liver Dis 2010;19:409–14.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Saracino IM, Zullo A, Holton J, Castelli V, Fiorini G, Zaccaro C, et al. High prevalence of primary antibiotic resistance in helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis 2012;21:363–5.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, et al. Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206–14.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Saika T, Muraoka H, Murakami K, Fujioka T. Helicobacter pylori isolated from patients who later failed H. pylori eradication triple therapy readily develop resistance to clarithromycin. J Med Microbiol 2006;55:737–40.
   PubMed Web of Science ®Google Scholar
• Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009;14:86–90.
   PubMed Web of Science ®Google Scholar
• Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-helicobacter pylori therapy using an extended 14-Day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter 2012;17:374–81.
   PubMed Web of Science ®Google Scholar
• Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, et al. Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012;35:56–65.
   PubMed Web of Science ®Google Scholar
• Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, Bory F, Barenys M, Bujanda L, et al. High-dose, ten-day esomeprazole, Amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012;36:190–6.
   PubMed Web of Science ®Google Scholar
• Goh KL, Manikam J, Qua CS. High-dose rabeprazole–Amoxicillin dual therapy and rabeprazole triple therapy with Amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2012;35:1097–102.
   PubMed Web of Science ®Google Scholar
• McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414–25.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001;13:1303–7.
   PubMed Web of Science ®Google Scholar
• De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004;36:322–6.
   PubMedGoogle Scholar
• Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002;97:857–60.
   PubMed Web of Science ®Google Scholar
• Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002;35:315–20.
   PubMed Web of Science ®Google Scholar
• Boixeda D, Bermejo F, Martín-De-Argila C, López-Sanromán A, Defarges V, Hernández-Ranz F, et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Am J Gastroenterol 2002;16:1457–60.
   Google Scholar